MedPath

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

Phase 3
Completed
Conditions
General Anxiety Disorder
Registration Number
NCT00233675
Lead Sponsor
Cephalon
Brief Summary

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (26)

Pivotal Research Center

🇺🇸

Mesa, Arizona, United States

Southwestern Research

🇺🇸

Beverly Hills, California, United States

Pharmacology Research Institut

🇺🇸

Northridge, California, United States

Pacific Clinical Research Medi

🇺🇸

Orange, California, United States

Radiant Research San Diego

🇺🇸

San Diego, California, United States

Affiliated Research Institute

🇺🇸

San Diego, California, United States

Radiant Research Denver

🇺🇸

Denver, Colorado, United States

University of Connecticut

🇺🇸

Farmington, Connecticut, United States

Clinical Neuroscience Solution

🇺🇸

West Palm Beach, Florida, United States

Carman Research

🇺🇸

Smyrna, Georgia, United States

Scroll for more (16 remaining)
Pivotal Research Center
🇺🇸Mesa, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.